Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Pediatric Patients

Study Identifier
191622-120
CT.gov Identifier
EudraCT Identifier
EUCTIS ID
Not available
For general inquiries, please contact
Study Complete

Results Available

Statistical Analysis Plan
Available Language(s): English
Protocol
Available Language(s): English

Study Details

Medical Condition
  • Bladder Disorder - Overactive Bladder
  • Study Drug
  • OnabotulinumtoxinA
  • Phase
    Phase 3
    Sex
    Female & Male
    Age
    5 - 17 Years

    Protocol Summary

    This study will evaluate the 3 doses of onabotulinumtoxinA (botulinum toxin Type A) for the treatment of urinary incontinence due to neurogenic detrusor overactivity in pediatric participants between the ages of 5 to 17 years to determine if 1 or more doses were safe and effective.

    Study Locations

    Location
    Status
    Location
    University of Alabama at Birmingham
    Birmingham, Alabama, United States, 35233
    Status
    Not applicable
    Location
    Cedars-Sinai Medical Center
    Los Angeles, California, United States, 90048
    Status
    Not applicable
    Location
    Children's Hospital of Orange County
    Orange, California, United States, 92868
    Status
    Not applicable
    Location
    Ann & Robert H. Lurie Children's Hospital of Chicago
    Chicago, Illinois, United States, 60611
    Status
    Not applicable
    Location
    Riley Hospital for Children
    Indianapolis, Indiana, United States, 46032
    Status
    Not applicable
    Location
    William Beaumont Hospital Research Institute
    Royal Oak, Michigan, United States, 48073
    Status
    Not applicable
    Showing {first} - {last} of {total} Results